Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACE: Tislelizumab + Chemotherapy for Neoadjuvant AEG
NCT06469060Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in adenocarcinoma of the esophagogastric junction (AEG), sponsored by Shanghai Chest Hospital. Primary endpoint: Pathological Complete Response Rate at 12 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
adenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT06469060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469060.